Phyllocontin (aminophylline) Continus 225mg and Phyllocontin Forte Continus 350mg modified-release tablets by Napp Pharmaceuticals are being discontinued in the UK, the Department of Health and Social Care (DH) said in a drug supply alert on Tuesday (Feb 9).
The remaining supplies of the 225mg strength are expected to be exhausted by March 2, whereas the 350mg strengths are likely to remain unavailable from April 5.
Prescribers have been suggested to review all affected patients and optimise inhaled therapies. The patients, who still require a methylxanthine, will need to be switched to theophylline tablets (Uniphyllin Continus).
UL Global will be able to source very limited quantities of aminophylline 225mg modified release tablets, the DH has said.
Phyllocontin is used in adults for the treatment and prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease, and chronic bronchitis. For children, it is used for the management of asthma.
Napp Pharmaceuticals, the sole supplier of oral aminophylline has discontinued the drug as part of its commercial decision.